|
|
- 2016
新型肽VIP-TAT对NMDA诱导的大鼠视网膜损伤的神经保护作用
|
Abstract:
摘要 目的研究新型肽VIP-TAT(血管活性肠肽重组肽)对NMDA(N-甲基-D-天门冬氨酸)诱导的大鼠视网膜损伤的神经保护作用.方法:向SD大鼠双眼玻璃体腔注射40nmol NMDA (2 μL)建立视网膜损伤模型,治疗组向玻璃体腔注射2 μL不同浓度(10 pmol/L、1 nmol/L、100 nmol/L、10 μmol/L)的VIP-TAT,NMDA组用等体积生理盐水替代,正常对照组不作任何处理.分别于术后7天用黑白箱装置对其行为学进行检测,观察每组大鼠术后视觉行为的变化;采用视网膜电图评估每组大鼠视功能的差异;石蜡切片HE染色比较各组大鼠视网膜形态学的差异.结果:行为学检测显示,各组大鼠在暗室停留时间的无统计学差异(P>0.05);视网膜电图检测结果表明浓度为1 nmol/L的VIP-TAT能够显著提高因NMDA损伤而降低的b波与明视负向反应(PhNR)的振幅;HE染色显示:在NMDA诱导的青光眼模型中,浓度为1 nmol/L的VIP-TAT能有效增加NMDA诱导的青光眼模型视中视网膜神经节细胞的存活数目.结论:NMDA诱导的SD 大鼠青光眼模型中,VIP-TAT对视网膜神经节细胞有保护作用.
| [1] | 葛 坚. 青光眼基本问题的研究现状及展望[G].中华医学会第九届全国眼科学术大会论文汇编,2004:28. |
| [2] | LI Y, SCHLAMP C L, NICKELLS R W. Experimental induction of retinal ganglion cell death in adult mice[J]. Invest Ophthalmol Vis Sci, 1999, 40(5):1004-1008. |
| [3] | SCHLAMP C L, JOHNSON E C, LI Y, et al. Changes in Thy1 gene expression associated with damaged retinal ganglion cells[J]. Mol Vis, 2001,7(27):192-201. |
| [4] | CASSON R J, CHIDLOW G, WOOD J P, et al. The effect of retinal ganglion cell injury on light-induced photoreceptor degeneration[J]. Invest Ophthalmol Vis Sci, 2004, 45(2):685-693. |
| [5] | VISWANATHAN S, FRISHMAN L J, ROBSON J G, et al. The photopic negative response of the flash electroretinogram in primary open angle glaucoma[J]. Invest Ophthalmol Vis Sci, 2001, 42(2):514-522. |
| [6] | CHEN H, ZHANG M, HUANG S, et al. The photopic negative response of flash ERG in nonproliferative diabetic retinopathy[J]. Doc Ophthalmol, 2008, 117(2):129-135. |
| [7] | LI B, BARNES G E, HOLT W F. The decline of the photopic negative response (PhNR) in the rat after optic nerve transection[J]. Doc Ophthalmol, 2005, 111(1):23-31. |
| [8] | LAM T T, ABLER A S, KWONG J M, et al. N-methyl-D-aspartate (NMDA)——induced apoptosis in rat retina[J]. Invest Ophthalmol Vis Sci, 1999,40(10):2391-2397. |
| [9] | YU R, YANG Y, CUI Z, et al. Novel peptide VIP-TAT with higher affinity for PAC1 inhibited scopolamine induced amnesia[J]. Peptides, 2014, 60:41-50. |
| [10] | JEHLE T, DIMITRIU C, AUER S, et al. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush[J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246(9):1255-1263. |
| [11] | TROGER J, NEYER S, HEUFLER C, et al. Substance P and vasoactive intestinal polypeptide in the streptozotocin-induced diabetic rat retina[J]. Invest Ophthalmol Vis Sci, 2001, 42(5):1045-1050. |
| [12] | LIN B, KOIZUMI A, TANAKA N, et al. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin[J]. Proc Natl Acad Sci USA, 2008, 105(41):16009-16014. |
| [13] | QUIGLEY H A, BROMAN A T. The number of people with glaucoma worldwide in 2010 and 2020[J]. Br J Ophthalmol, 2006, 90(3):262-267. |
| [14] | THAM Y C, LI X, WONG T Y, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis[J]. Ophthalmology, 2014, 121(11):2081-2090. |
| [15] | KUEHN M H, FINGERT J H, KWON Y H. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies[J]. Ophthalmol Clin North Am, 2005, 18(3):383-395. |
